Chromadex Corp
CDXC
Market Cap$611.9M
Close$
$-0.10
101.3% downside
Current Fair Value
101.3% downsideOvervalued by 101.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $611.90 Million |
|---|---|
| Enterprise Value | $555.02 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.11 |
| Beta | 2.21 |
| Outstanding Shares | 79,249,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 44.25 |
|---|---|
| PEG | -0.18 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.67 |
| Enterprise Value to EBIT | 34.03 |
| Enterprise Value to Net Income | 31 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Chromadex Corp
CEO: Robert Fried ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solut...